stockrowPfizer Inc.
PFE Healthcare Drug Manufacturers General
Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024.
- Revenue
- −0.43%
- EPS
- −7.98%
- Free cash flow
- +20.0%
- Total debt
- +1.55%
Quarter to September 2026, against a year earlier
Follow PFE
Alert me
Pfizer Inc. (PFE) Operating cash flow
Pfizer Inc.'s operating cash flow for fiscal 2025 was $11.7B, down 8.16% from $12.7B in fiscal 2024. Over the twelve months to 30 September 2026 it was $14.2B. Over the past ten years it has ranged from $8.7B (fiscal 2023) to $32.6B (fiscal 2021); the current reading is higher than 18% of that period. Pfizer Inc. ranks 9th of 21 Drug Manufacturers General companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $11.7B | (8.16%) |
| FY2024 | $12.7B | 46.48% |
| FY2023 | $8.7B | (70.27%) |
| FY2022 | $29.3B | (10.17%) |
| FY2021 | $32.6B | 126.20% |
| FY2020 | $14.4B | 14.42% |
| FY2019 | $12.6B | (20.47%) |
| FY2018 | $15.8B | (5.80%) |
| FY2017 | $16.8B | 3.77% |
| FY2016 | $16.2B | 10.24% |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $5.4B | 543.71% |
| Jun 2026 | $835.0M | (68.07%) |
| Mar 2026 | $2.6B | (51.10%) |
| Dec 2025 | $5.3B | 16.19% |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| SNY Sanofi compare | $23.8B |
| NVO Novo Nordisk A/S compare | $20.4B |
| NVS Novartis AG compare | $17.3B |
| GILD Gilead Sciences, Inc. compare | $14.5B |
| PFE Pfizer Inc. | $14.2B |
| AZN AstraZeneca PLC compare | $13.2B |
| AMGN Amgen Inc. compare | $12.0B |
| GSK GSK PLC Sponsored ADR compare | $11.8B |
| BMY Bristol Myers Squibb Company compare | $10.7B |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on PFE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement